- Home
- BY vs KRSA Comparison
BY vs KRSA Comparison
Compare BY & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BY | KRSA |
|---|---|---|
| Founded | 1914 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BY | KRSA |
|---|---|---|
| Price | $39.22 | $32.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $44.40 | $44.00 |
| AVG Volume (30 Days) | ★ 205.7K | 158.7K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | 5.09 | ★ 8.26 |
| EPS | ★ 2.67 | N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | $5.41 | N/A |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $14.62 | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $26.42 | $29.03 |
| 52 Week High | $40.05 | $37.27 |
Technical Indicators
Market Signals| Indicator | BY | KRSA |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 50.47 |
| Support Level | $37.84 | $29.67 |
| Resistance Level | $39.53 | $34.51 |
| Average True Range (ATR) | 0.75 | 1.87 |
| MACD | 0.05 | 0.18 |
| Stochastic Oscillator | 67.91 | 64.84 |
Price Performance
Historical ComparisonAbout BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through a wholly-owned subsidiary of Byline Bank.
About KRSA Korsana Biosciences Inc. Common Stock
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.